Radient Pharmaceuticals Corporation fka RXPC

[lakeshore555]

Notice it says "Per Mouse." CIT has never been tested on humans.

CIT is dead. Radient wrote it off as a 100% loss in their final 10-K with the explanation that it was not worth developing.

Chang stopped working on CIT when he sold it to AMDL/Radient over a decade ago, and has since been working on immunotherapy at Florida. NuVax (subsidiary of Radient) hired Chang in 2011 and decided in Dec 2011 and January 2012 to abandon CIT and invest in Chang's newer technology. That is all documented in the final 10-K.

Unfortunately, Radient then stopped paying Chang, and he left NuVax. Chang is available. If someone wanted to invest in Chang's immunotherapy work, they would invest in his newer work at Florida, not CIT.